Insights from nanomedicine into chloroquine efficacy against COVID-19

Tony Y Hu, Matthew Frieman, Joy Wolfram, Tony Y Hu, Matthew Frieman, Joy Wolfram

Abstract

Chloroquine — an approved malaria drug — is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19.

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1. Potential mechanism by which chloroquine…
Fig. 1. Potential mechanism by which chloroquine exerts therapeutic effects against COVID-19.
The proposed mechanism involves chloroquine-induced suppression of PICALM, which prevents endocytosis-mediated uptake of SARS-CoV-2.

References

    1. Gao, J., Tian, Z. & Yang, X. Biosci. Trends10.5582/bst.2020.01047 (2020).
    1. Wang M, et al. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
    1. Zhu N, et al. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.
    1. Haladyj E, Sikora M, Felis-Giemza A, Olesinska M. Reumatologia. 2018;56:164–173. doi: 10.5114/reum.2018.76904.
    1. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Lancet Infect. Dis. 2003;3:722–727. doi: 10.1016/S1473-3099(03)00806-5.
    1. Keyaerts E, et al. Antimicrob. Agents Chemother. 2009;53:3416–3421. doi: 10.1128/AAC.01509-08.
    1. Vincent MJ, et al. Virol. J. 2005;2:69. doi: 10.1186/1743-422X-2-69.
    1. Hempelmann E. Parasitol. Res. 2007;100:671–676. doi: 10.1007/s00436-006-0313-x.
    1. Pelt J, et al. Pharmacol. Ther. 2018;191:43–49. doi: 10.1016/j.pharmthera.2018.06.007.
    1. Wolfram J, et al. Sci Rep. 2017;7:13738. doi: 10.1038/s41598-017-14221-2.
    1. Miller SE, et al. Dev. Cell. 2015;33:163–175. doi: 10.1016/j.devcel.2015.03.002.
    1. Wolfram J, Ferrari M. Nano Today. 2019;25:85–89. doi: 10.1016/j.nantod.2019.02.005.
    1. Gentile E, et al. Future Oncol. 2013;9:1849–1859. doi: 10.2217/fon.13.146.
    1. Wu K, Li W, Peng G, Li F. Proc. Natl Acad. Sci. USA. 2009;106:19970–19974. doi: 10.1073/pnas.0908837106.
    1. Li W, et al. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
    1. Wang H, et al. Cell Res. 2008;18:290–301. doi: 10.1038/cr.2008.15.
    1. Inoue Y, et al. J. Virol. 2007;81:8722–8729. doi: 10.1128/JVI.00253-07.
    1. Wrapp D, et al. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.
    1. Yao, X. et al. Clin. Infect. Dis.10.1093/cid/ciaa237 (2020).
    1. Liu J, et al. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-0.
    1. Dowall SD, et al. J. Gen. Virol. 2015;96:3484–3492. doi: 10.1099/jgv.0.000309.
    1. Madrid PB, et al. PLoS One. 2013;8:e60579. doi: 10.1371/journal.pone.0060579.
    1. Roques P, et al. Viruses. 2018;10:268. doi: 10.3390/v10050268.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera